Pharmacological inhibition of diacylglycerol acyltransferase 1 reduces body weight gain, hyperlipidemia, and hepatic steatosis in db/db mice

Acta Pharmacologica Sinica

Volumn 31, Issue 11, 2010, Pages 1470-1477

  Zhang, Xiao Dong ^a   Yan, Jian Wei ^a   Yan, Gui Rui ^a   Sun, Xiao Yun ^a   Ji, Jun ^a   Li, Yi Ming ^b   Hu, You Hong ^a   Wang, He Yao ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

CPT1 gene; db db mice; diabetes; diacylglycerol acyltransferase 1; H128; hepatic steatosis; hyperlipidemia; obesity; PPAR gene; small molecule inhibitor

Indexed keywords

ACYLTRANSFERASE INHIBITOR; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CARNITINE PALMITOYLTRANSFERASE I; CORN OIL; DIACYLGLYCEROL ACYLTRANSFERASE 1; FAT DROPLET; GLUCOSE; H 128; H128; INSULIN; LEPTIN RECEPTOR; LIPID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; FATTY ACID OXIDATION; FATTY LIVER; FEEDING; FOOD INTAKE; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HYPERLIPIDEMIA; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; LIPID ABSORPTION; LIVER WEIGHT; MALE; METABOLIC DISORDER; MOUSE; NONHUMAN; OBESITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ANIMALS; BIPHENYL COMPOUNDS; BLOOD GLUCOSE; DIACYLGLYCEROL O-ACYLTRANSFERASE; EATING; ENZYME INHIBITORS; FATTY ACIDS; FATTY LIVER; HYPERLIPIDEMIAS; INSULIN RESISTANCE; LIVER; MALE; MICE; MICE, KNOCKOUT; PHENYLUREA COMPOUNDS; RECEPTORS, LEPTIN; TRIGLYCERIDES; WEIGHT GAIN;

EID: 78149368672     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2010.104     Document Type: Article

References (36)

1. LeRoith D. Dyslipidemia and glucose dysregulation in overweight and obese patients. Clin Cornerstone 2007; 8: 38-52.
2. Bray GA, Bellanger T. Epidemiology, trends, and morbidities of obesity and the metabolic syndrome. Endocrine 2006; 29: 109-17.
3. Heber D. An integrative view of obesity. Am J Clin Nutr 2010; 91: 280S-83S.
4. Chen HC, Farese RV Jr. Inhibition of triglyceride synthesis as a treatment strategy for obesity: lessons from DGAT1-deficient mice. Arterioscler Thromb Vasc Biol 2005; 25: 482-6.
5. Dickerson LM, Carek PJ. Pharmacotherapy for the obese patient. Prim Care 2009; 36: 407-15.
6. Buhman KK, Chen HC, Farese RV Jr. The enzymes of neutral lipid synthesis. J Biol Chem 2001; 276: 40369-72.
7. Cases S, Smith SJ, Zheng YW, Myers HM, Lear SR, Sande E, et al. Identification of a gene encoding an acyl CoA:diacylglycerol acyltransferase, a key enzyme in triacylglycerol synthesis. Proc Natl Acad Sci USA 1998; 95: 13018-23.
8. Cases S, Stone SJ, Zhou P, Yen E, Tow B, Lardizabal KD, et al. Cloning of DGAT2, a second mammalian diacylglycerol acyltransferase, and related family members. J Biol Chem 2001; 276: 38870-6.
9. Yen CL, Stone SJ, Koliwad S, Harris C, Farese RV Jr. Thematic review series: glycerolipids. DGAT enzymes and triacylglycerol biosynthesis. J Lipid Res 2008; 49: 2283-301.
10. Stone SJ, Myers HM, Watkins SM, Brown BE, Feingold KR, Elias PM, et al. Lipopenia and skin barrier abnormalities in DGAT2-deficient mice. J Biol Chem 2004; 279: 11767-76.
11. Chen HC, Ladha Z, Smith SJ, Farese RV Jr. Analysis of energy expenditure at different ambient temperatures in mice lacking DGAT1. Am J Physiol Endocrinol Metab 2003; 284: E213-8.
12. Chen HC, Smith SJ, Ladha Z, Jensen DR, Ferreira LD, Pulawa LK, et al. Increased insulin and leptin sensitivity in mice lacking acyl CoA:diacylglycerol acyltransferase 1. J Clin Invest 2002; 109: 1049-55.
13. Smith SJ, Cases S, Jensen DR, Chen HC, Sande E, Tow B, et al. Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat. Nat Genet 2000; 25: 87-90.
14. Chen HC, Rao M, Sajan MP, Standaert M, Kanoh Y, Miura A, et al. Role of adipocyte-derived factors in enhancing insulin signaling in skeletal muscle and white adipose tissue of mice lacking Acyl CoA:diacylglycerol acyltransferase 1. Diabetes 2004; 53: 1445-51.
15. Villanueva CJ, Monetti M, Shih M, Zhou P, Watkins SM, Bhanot S, et al. Specific role for acyl CoA:Diacylglycerol acyltransferase 1 (Dgat1) in hepatic steatosis due to exogenous fatty acids. Hepatology 2009; 50: 434-42.
16. Matsuda D, Tomoda H. DGAT inhibitors for obesity. Curr Opin Investig Drugs 2007; 8: 836-41.
17. Chen HC, Farese RV Jr. DGAT and triglyceride synthesis: a new target for obesity treatment? Trends Cardiovasc Med 2000; 10: 188-92.
18. Birch AM, Birtles S, Buckett LK, Kemmitt PD, Smith GJ, Smith TJ, et al. Discovery of a potent, selective, and orally efficacious pyrimidinooxazinyl bicyclooctaneacetic acid diacylglycerol acyltransferase-1 inhibitor. J Med Chem 2009; 52: 1558-68.
19. Zhao G, Souers AJ, Voorbach M, Falls HD, Droz B, Brodjian S, et al. Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor. J Med Chem 2008; 51: 380-3.
20. Cool B, Zinker B, Chiou W, Kifle L, Cao N, Perham M, et al. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab 2006; 3: 403-16.
21. Goepfert S, Poirier Y. Beta-oxidation in fatty acid degradation and beyond. Curr Opin Plant Biol 2007; 10: 245-51.
22. Nakamura MT, Nara TY. Essential fatty acid synthesis and its regulation in mammals. Prostaglandins Leukot Essent Fatty Acids 2003; 68: 145-50.
23. Buhman KK, Smith SJ, Stone SJ, Repa JJ, Wong JS, Knapp FF Jr, et al. DGAT1 is not essential for intestinal triacylglycerol absorption or chylomicron synthesis. J Biol Chem 2002; 277: 25474-9.
24. Cheng D, Iqbal J, Devenny J, Chu CH, Chen L, Dong J, et al. Acylation of acylglycerols by acyl coenzyme A:diacylglycerol acyltransferase 1 (DGAT1). Functional importance of DGAT1 in the intestinal fat absorption. J Biol Chem 2008; 283: 29802-11.
25. Shi Y, Cheng D. Beyond triglyceride synthesis: the dynamic functional roles of MGAT and DGAT enzymes in energy metabolism. Am J Physiol Endocrinol Metab 2009; 297: E10-8.
26. Thupari JN, Landree LE, Ronnett GV, Kuhajda FP. C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity. Proc Natl Acad Sci USA 2002; 99: 9498-502.
27. Bebernitz GR, Schuster HF. The impact of fatty acid oxidation on energy utilization: targets and therapy. Curr Pharm Des 2002; 8: 1199-227.
28. Minokoshi Y, Kim YB, Peroni OD, Fryer LG, Muller C, Carling D, et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 2002; 415: 339-43.
29. Suzuki A, Okamoto S, Lee S, Saito K, Shiuchi T, Minokoshi Y. Leptin stimulates fatty acid oxidation and peroxisome proliferator-activated receptor alpha gene expression in mouse C2C12 myoblasts by changing the subcellular localization of the alpha2 form of AMP-activated protein kinase. Mol Cell Biol 2007; 27: 4317-27.
30. Farese RV Jr, Cases S, Smith SJ. Triglyceride synthesis: insights from the cloning of diacylglycerol acyltransferase. Curr Opin Lipidol 2000; 11: 229-34.
31. Kohjima M, Enjoji M, Higuchi N, Kato M, Kotoh K, Yoshimoto T, et al. Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease. Int J Mol Med 2007; 20: 351-8.
32. Marchesini G, Marzocchi R, Agostini F, Bugianesi E. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol 2005; 16: 421-7.
33. Petersen KF, Shulman GI. Etiology of insulin resistance. Am J Med 2006; 119: S10-6.
34. Kelley DE, McKolanis TM, Hegazi RA, Kuller LH, Kalhan SC. Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. Am J Physiol Endocrinol Metab 2003; 285: E906-16.
35. Monetti M, Levin MC, Watt MJ, Sajan MP, Marmor S, Hubbard BK, et al. Dissociation of hepatic steatosis and insulin resistance in mice overexpressing DGAT in the liver. Cell Metab 2007; 6: 69-78.
36. Shah S, Iqbal M, Karam J, Salifu M, McFarlane SI. Oxidative stress, glucose metabolism, and the prevention of type 2 diabetes: pathophysiological insights. Antioxid Redox Signal 2007; 9: 911-29